...
首页> 外文期刊>Qatar Medical Journal >Reduction in ECMO mortality following increased experience: The Dubai Hospital experience
【24h】

Reduction in ECMO mortality following increased experience: The Dubai Hospital experience

机译:通过增加经验减少ECMO死亡率:迪拜医院经验

获取原文
           

摘要

Background: Survival following extracorporeal membrane oxygenation (ECMO) has steadily improved over the past decade owing to better knowledge and training. 1,2 The objective of our study is to identify the predictors and trend of in-hospital morbidity and mortality during our initial experience. Methods: After obtaining an DSREC (Dubai Scientific Research Ethics Committee) review and exemption, we collected the clinical data of patients from May 2013 to November 2016 and analyzed for baseline characteristics, indication, type, undergoing cardiopulmonary resuscitation (CPR) or not, duration of ECMO treatment, morbidity, and mortality. Results: A total of 24 adults received ECMO (18 M/6 F), of which 22 were supported with veno-arterial (VA) ECMO and the remaining were converted from VA to veno-venous (VV) ECMO during the course of their treatment. There were 8 (6 M/2 F) survivors (30%) with two bridged for left ventricular assist device (LVAD) and one for heart transplant. The mortality pattern as shown in Figure 1 shows a consistent improvement of more than 50% from mid-2015. Weaning was overall successful in 30% of surgical and 38% of medical patients. CPR was necessary in 12 patients, none from the survivor group. The minimum to maximum duration of ECMO was 53–483 hours in the survivors versus 2–528 hours in the non-survivors, of which 8 (50%) survived less than 24 hours on ECMO. The most frequent complications were bleeding from catheterization or surgical site (58.3%), renal failure (29.1%), GI bleeding (20.8%), and leg ischemia (12.5%). Two patients had raised bilirubin and one altered response to medication, resulting in hypertension and bleeding. 3 The percentage among survivors to non-survivors with reference to bleeding was 38% vs. 69%, leg ischemia 0% vs.18%, renal failure 12.5% vs. 37.5%, and GI bleeding 12.5% vs. 31.2%.
机译:背景:在过去的十年中,由于更好的知识和培训,体外膜氧合(ECMO)后的存活率稳步提高。 1,2本研究的目的是在我们的初步经验中确定医院内发病率和死亡率的预测因素和趋势。方法:在获得迪拜科学研究伦理委员会的DSREC审查和豁免后,我们收集了2013年5月至2016年11月患者的临床数据,并分析了基线特征,适应症,类型,是否接受心肺复苏(CPR),持续时间ECMO的治疗,发病率和死亡率。结果:总共有24位成人接受ECMO(18 M / 6 F),其中22位接受了静脉-动脉(VA)ECMO的支持,其余的在他们的过程中从VA转换为静脉-静脉(VV)ECMO治疗。有8名(6 M / 2 F)幸存者(30%),其中两个桥接用于左心室辅助装置(LVAD),一个桥接用于心脏移植。如图1所示的死亡率模式显示,与2015年中期相比,死亡率持续提高了50%以上。总体而言,有30%的手术患者和38%的内科患者断奶成功。 12例患者必须进行CPR,幸存者组无一例。 ECMO的最小到最大持续时间在幸存者中为53–483小时,而非幸存者为2–528小时,其中8个(50%)在ECMO上存活不到24小时。最常见的并发症是导管或手术部位出血(58.3%),肾衰竭(29.1%),胃肠道出血(20.8%)和腿部缺血(12.5%)。两名患者的胆红素升高,一名对药物反应改变,导致高血压和出血。 3就出血而言,幸存者与非幸存者的比例分别为38%对69%,下肢缺血0%对18%,肾衰竭12.5%对37.5%,胃肠道出血12.5%对31.2%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号